ARDELYX, INC. Other-than-temporary Impairment Loss, Debt Securities, Available-for-sale
ARDELYX, INC. (ARDX) reported Other-than-temporary Impairment Loss, Debt Securities, Available-for-sale of $0 for the 3-month period ending 2022-03-31, per its 10-Q filed 2022-05-05.
Discontinued › Expense Statement › Operating Expenses
us-gaap:OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale · last filed 2022-05-05
- ARDELYX, INC. other-than-temporary impairment loss, debt securities, available-for-sale for the quarter ending 2022-03-31 was $0.00.
- ARDELYX, INC. other-than-temporary impairment loss, debt securities, available-for-sale for the quarter ending 2021-12-31 was $0.00.
- ARDELYX, INC. other-than-temporary impairment loss, debt securities, available-for-sale for the quarter ending 2021-09-30 was $0.00.
- ARDELYX, INC. other-than-temporary impairment loss, debt securities, available-for-sale for the quarter ending 2021-06-30 was $0.00.
- ARDELYX, INC. other-than-temporary impairment loss, debt securities, available-for-sale for fiscal 2021 was $0.00.
- ARDELYX, INC. other-than-temporary impairment loss, debt securities, available-for-sale for fiscal 2020 was $0.00.
- ARDELYX, INC. other-than-temporary impairment loss, debt securities, available-for-sale for fiscal 2019 was $0.00.
| Period end | Other-than-temporary Impairment Loss, Debt Securities, Available-for-sale 3 month | Other-than-temporary Impairment Loss, Debt Securities, Available-for-sale 6 month | Other-than-temporary Impairment Loss, Debt Securities, Available-for-sale 9 month | Other-than-temporary Impairment Loss, Debt Securities, Available-for-sale 12 month |
|---|---|---|---|---|
| 2022-03-31 | $0.00 10-Q · filed 2022-05-05 | $0.00 derived: sum of 2 quarters · filed 2022-05-05 | $0.00 derived: sum of 3 quarters · filed 2022-05-05 | $0.00 derived: sum of 4 quarters · filed 2022-05-05 |
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | $0.00 derived: sum of 2 quarters · filed 2022-02-28 | $0.00 derived: sum of 3 quarters · filed 2022-02-28 | $0.00 10-K · filed 2022-02-28 |
| 2021-09-30 | $0.00 10-Q · filed 2021-11-12 | $0.00 derived: sum of 2 quarters · filed 2021-11-12 | $0.00 10-Q · filed 2021-11-12 | $0.00 derived: sum of 4 quarters · filed 2022-05-05 |
| 2021-06-30 | $0.00 10-Q · filed 2021-08-13 | $0.00 10-Q · filed 2021-08-13 | $0.00 derived: sum of 3 quarters · filed 2022-05-05 | $0.00 derived: sum of 4 quarters · filed 2022-05-05 |
| 2021-03-31 | $0.00 10-Q · filed 2022-05-05 | $0.00 derived: sum of 2 quarters · filed 2022-05-05 | $0.00 derived: sum of 3 quarters · filed 2022-05-05 | $0.00 derived: sum of 4 quarters · filed 2022-05-05 |
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | $0.00 derived: sum of 2 quarters · filed 2022-02-28 | $0.00 derived: sum of 3 quarters · filed 2022-02-28 | $0.00 10-K · filed 2022-02-28 |
| 2020-09-30 | $0.00 10-Q · filed 2021-11-12 | $0.00 derived: sum of 2 quarters · filed 2021-11-12 | $0.00 10-Q · filed 2021-11-12 | |
| 2020-06-30 | $0.00 10-Q · filed 2021-08-13 | $0.00 10-Q · filed 2021-08-13 | ||
| 2020-03-31 | $0.00 10-Q · filed 2021-05-06 | |||
| 2019-12-31 | $0.00 10-K · filed 2022-02-28 | |||
| 2019-03-31 | $0.00 10-Q · filed 2020-05-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 | |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |